Suppr超能文献

β-干扰素对严重急性呼吸综合征冠状病毒的抗病毒作用并非由Mx A蛋白介导。

The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.

作者信息

Spiegel Martin, Pichlmair Andreas, Mühlberger Elke, Haller Otto, Weber Friedemann

机构信息

Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, D-79008 Freiburg, Germany.

出版信息

J Clin Virol. 2004 Jul;30(3):211-3. doi: 10.1016/j.jcv.2003.11.013.

DOI:10.1016/j.jcv.2003.11.013
PMID:15135736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7128634/
Abstract

Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus termed SARS-CoV. No antiviral treatment has been established so far. Interferons are cytokines which induce the synthesis of several antivirally active proteins in the cell. In this study, we demonstrated that multiplication of SARS-CoV in cell culture can be strongly inhibited by pretreatment with interferon-beta. Interferon-alpha and interferon-gamma, by contrast, were less effective. The human MxA protein is one of the most prominent proteins induced by interferon-beta. Nevertheless, no interference with SARS-CoV replication was observed in Vero cells stably expressing MxA. Therefore, other interferon-induced proteins must be responsible for the strong inhibitory effect of interferon-beta against SARS-CoV.

摘要

严重急性呼吸综合征（SARS）由一种名为SARS-CoV的新型冠状病毒引起。目前尚未确立抗病毒治疗方法。干扰素是一类能诱导细胞合成多种抗病毒活性蛋白的细胞因子。在本研究中，我们证明了用β干扰素预处理可强烈抑制SARS-CoV在细胞培养中的增殖。相比之下，α干扰素和γ干扰素的效果较差。人Mx A蛋白是β干扰素诱导产生的最显著的蛋白之一。然而，在稳定表达Mx A的非洲绿猴肾细胞（Vero细胞）中未观察到对SARS-CoV复制的干扰。因此，必定是其他干扰素诱导蛋白介导了β干扰素对SARS-CoV的强烈抑制作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c994/7128634/7d61470cf5cc/gr1.jpg

相似文献

1
The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.
J Clin Virol. 2004 Jul;30(3):211-3. doi: 10.1016/j.jcv.2003.11.013.
2
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Antivir Ther. 2004 Dec;9(6):1003-11.
3
Interferon-beta 1a and SARS coronavirus replication.
Emerg Infect Dis. 2004 Feb;10(2):317-9. doi: 10.3201/eid1002.030482.
4
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
5
In vitro inhibition of SARS virus replication by human interferons.
Scand J Infect Dis. 2004;36(11-12):829-31. doi: 10.1080/00365540410021144.
6
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.
Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8. doi: 10.1016/j.bbrc.2004.11.128.
7
The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
Intervirology. 2007;50(2):156-60. doi: 10.1159/000098242. Epub 2006 Dec 22.
8
Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
Virology. 2006 Sep 30;353(2):474-81. doi: 10.1016/j.virol.2006.06.011. Epub 2006 Jul 24.
9
Significance of the myxovirus resistance A (MxA) gene -123C>a single-nucleotide polymorphism in suppressed interferon beta induction of severe acute respiratory syndrome coronavirus infection.
J Infect Dis. 2010 Jun 15;201(12):1899-908. doi: 10.1086/652799.
10
Inhibition of SARS-CoV replication by siRNA.
Antiviral Res. 2005 Jan;65(1):45-8. doi: 10.1016/j.antiviral.2004.09.005.

引用本文的文献

1
The Wnt/β-catenin pathway is important for replication of SARS-CoV-2 and other pathogenic RNA viruses.
Npj Viruses. 2024 Feb 21;2(1):6. doi: 10.1038/s44298-024-00018-4.
2
Harnessing the power of IFN for therapeutic approaches to COVID-19.
J Virol. 2024 May 14;98(5):e0120423. doi: 10.1128/jvi.01204-23. Epub 2024 Apr 23.
3
-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.
Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309.
4
Study of the effects of interferon β-1a on hospitalized patients with COVID-19: SBMU Taskforce on the COVIFERON study.
J Med Virol. 2022 Apr;94(4):1488-1493. doi: 10.1002/jmv.27475. Epub 2021 Nov 30.
5
Identification and Development of Therapeutics for COVID-19.
mSystems. 2021 Dec 21;6(6):e0023321. doi: 10.1128/mSystems.00233-21. Epub 2021 Nov 2.
6
Severe Acute Respiratory Syndrome Coronavirus 2: The Role of the Main Components of the Innate Immune System.
Inflammation. 2021 Dec;44(6):2151-2169. doi: 10.1007/s10753-021-01519-7. Epub 2021 Sep 15.
7
COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?
Pharmaceuticals (Basel). 2021 Jul 11;14(7):664. doi: 10.3390/ph14070664.
8
Bovine Coronavirus Immune Milk Against COVID-19.
Front Immunol. 2021 Mar 23;12:637152. doi: 10.3389/fimmu.2021.637152. eCollection 2021.
9
Identification and Development of Therapeutics for COVID-19.
ArXiv. 2021 Mar 3:arXiv:2103.02723v3.
10
Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus Reality.
J Inflamm Res. 2021 Jan 26;14:199-216. doi: 10.2147/JIR.S277716. eCollection 2021.

本文引用的文献

1
Coronavirus in severe acute respiratory syndrome (SARS).
Trends Mol Med. 2003 Aug;9(8):323-5. doi: 10.1016/s1471-4914(03)00135-7.
2
Treatment of SARS with human interferons.
Lancet. 2003 Jul 26;362(9380):293-4. doi: 10.1016/s0140-6736(03)13973-6.
3
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.
Lancet. 2003 Jul 26;362(9380):263-70. doi: 10.1016/S0140-6736(03)13967-0.
4
Aetiology: Koch's postulates fulfilled for SARS virus.
Nature. 2003 May 15;423(6937):240. doi: 10.1038/423240a.
5
Coronavirus as a possible cause of severe acute respiratory syndrome.
Lancet. 2003 Apr 19;361(9366):1319-25. doi: 10.1016/s0140-6736(03)13077-2.
6
A novel coronavirus associated with severe acute respiratory syndrome.
N Engl J Med. 2003 May 15;348(20):1953-66. doi: 10.1056/NEJMoa030781. Epub 2003 Apr 10.
7
Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
N Engl J Med. 2003 May 15;348(20):1967-76. doi: 10.1056/NEJMoa030747. Epub 2003 Apr 10.
8
Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity.
Traffic. 2002 Oct;3(10):710-7. doi: 10.1034/j.1600-0854.2002.31003.x.
9
Antiviral actions of interferons.
Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents. doi: 10.1128/CMR.14.4.778-809.2001.
10
Functional classification of interferon-stimulated genes identified using microarrays.
J Leukoc Biol. 2001 Jun;69(6):912-20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验